{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:22:26Z","timestamp":1788013346614,"version":"build-2784847793"},"reference-count":28,"publisher":"American Society of Hematology","issue":"1","license":[{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,9]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Idecabtagene vicleucel (ide-cel) was the first chimeric antigen receptor T-cell therapy to gain US Food and Drug Administration approval for patients with relapsed\/refractory multiple myeloma (RRMM). The clinical outcomes of standard of care (SOC) ide-cel in racially and ethnically diverse populations have been understudied. This study pooled data from 207 patients with RRMM (28% patients of racial and ethnic minority groups) treated with SOC ide-cel across 11 institutions to examine racial and ethnic differences in the incidence of toxicities and adverse events, response to ide-cel, and survival. This study included 22 (11%) Hispanic, 36 (17%) non-Hispanic Black, and 149 (72%) non-Hispanic White patients with RRMM. Compared with Hispanic and non-Hispanic White patients, non-Hispanic Black patients had higher median levels of C-reactive protein (1.0, 0.8, and 3.5\u00a0mg\/dL, respectively; P\u00a0= .02) and baseline ferritin (362.0 vs 307.0 vs 680.5, respectively; P\u00a0= .08) and were more likely to develop cytokine release syndrome (77%, 85%, and 97%, respectively; P\u00a0= .04). Although best overall response rate was lower among Hispanic patients (59%) than among non-Hispanic Black (86%) and White patients (86%; P\u00a0= .01), there were no racial and ethnic differences in progression-free or overall survival. We provide, to our knowledge, the first and largest investigation of clinical outcomes of SOC ide-cel by race and ethnicity. Despite differences in safety and response to ide-cel, our findings encourage the use of ide-cel in all patients with RRMM. These findings should be confirmed in larger samples of diverse patients with RRMM, with longer follow-up time.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023010894","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T14:01:12Z","timestamp":1697724072000},"page":"251-259","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":28,"title":["Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy"],"prefix":"10.1182","volume":"8","author":[{"given":"Lauren C.","family":"Peres","sequence":"first","affiliation":[{"name":"1Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6281-2512","authenticated-orcid":false,"given":"Laura B.","family":"Oswald","sequence":"additional","affiliation":[{"name":"2Department of Health Outcomes and Behavior, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7218-9960","authenticated-orcid":false,"given":"Christen M.","family":"Dillard","sequence":"additional","affiliation":[{"name":"3Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"De Avila","sequence":"additional","affiliation":[{"name":"4Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2621-7924","authenticated-orcid":false,"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[{"name":"4Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon J.","family":"Blue","sequence":"additional","affiliation":[{"name":"5Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0662-6480","authenticated-orcid":false,"given":"Ciara L.","family":"Freeman","sequence":"additional","affiliation":[{"name":"4Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[{"name":"4Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Alsina","sequence":"additional","affiliation":[{"name":"4Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0423-5870","authenticated-orcid":false,"given":"Omar","family":"Castaneda Puglianini","sequence":"additional","affiliation":[{"name":"4Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Shune","sequence":"additional","affiliation":[{"name":"6Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Medical Center, Kansas City, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4268-2698","authenticated-orcid":false,"given":"Douglas W.","family":"Sborov","sequence":"additional","affiliation":[{"name":"7Division of Hematology and Hematologic Malignancies, The University of Utah Huntsman Cancer Institute, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0568-0781","authenticated-orcid":false,"given":"Charlotte","family":"Wagner","sequence":"additional","affiliation":[{"name":"7Division of Hematology and Hematologic Malignancies, The University of Utah Huntsman Cancer Institute, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3587-7975","authenticated-orcid":false,"given":"Danai","family":"Dima","sequence":"additional","affiliation":[{"name":"8Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4129-5867","authenticated-orcid":false,"given":"Hamza","family":"Hashmi","sequence":"additional","affiliation":[{"name":"9Department of Hematology and Bone Marrow Transplant, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7978-1652","authenticated-orcid":false,"given":"James A.","family":"Davis","sequence":"additional","affiliation":[{"name":"10Department of Pharmacy, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9888-5737","authenticated-orcid":false,"given":"Mehmet H.","family":"Kocoglu","sequence":"additional","affiliation":[{"name":"11Division of Hematology\/Oncology, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1690-0188","authenticated-orcid":false,"given":"Ashraf Z.","family":"Badros","sequence":"additional","affiliation":[{"name":"11Division of Hematology\/Oncology, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shebli","family":"Atrash","sequence":"additional","affiliation":[{"name":"12Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Simmons","sequence":"additional","affiliation":[{"name":"13Cellular Immunotherapies and Transplant Program, Virginia Commonwealth University Massey Cancer Center, Richmond, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh","family":"Kalariya","sequence":"additional","affiliation":[{"name":"3Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2997-4856","authenticated-orcid":false,"given":"Christopher","family":"Ferreri","sequence":"additional","affiliation":[{"name":"3Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6531-9595","authenticated-orcid":false,"suffix":"Jr","given":"Larry D.","family":"Anderson","sequence":"additional","affiliation":[{"name":"14Myeloma, Waldenstrom\u2019s, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimaz","family":"Afrough","sequence":"additional","affiliation":[{"name":"14Myeloma, Waldenstrom\u2019s, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2510-6536","authenticated-orcid":false,"given":"Gurbakhash","family":"Kaur","sequence":"additional","affiliation":[{"name":"14Myeloma, Waldenstrom\u2019s, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"15Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8559-7739","authenticated-orcid":false,"given":"Lawrence","family":"Liu","sequence":"additional","affiliation":[{"name":"16City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Nadeem","sequence":"additional","affiliation":[{"name":"17Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1661-718X","authenticated-orcid":false,"given":"Peter","family":"Voorhees","sequence":"additional","affiliation":[{"name":"12Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2473-6528","authenticated-orcid":false,"given":"Jack","family":"Khouri","sequence":"additional","affiliation":[{"name":"8Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0539-4796","authenticated-orcid":false,"given":"Joseph","family":"McGuirk","sequence":"additional","affiliation":[{"name":"6Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Medical Center, Kansas City, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3288-7614","authenticated-orcid":false,"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[{"name":"18Division of Bone Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris K.","family":"Hansen","sequence":"additional","affiliation":[{"name":"4Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8894-027X","authenticated-orcid":false,"given":"Krina","family":"Patel","sequence":"additional","affiliation":[{"name":"3Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,1,9]]},"reference":[{"issue":"1","key":"2024010916393201600_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2024010916393201600_bib2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40265-017-0841-y","article-title":"Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update","volume":"78","author":"Nijhof","year":"2018","journal-title":"Drugs"},{"issue":"5","key":"2024010916393201600_bib3","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.clml.2019.10.002","article-title":"Treatment journeys of patients with newly diagnosed multiple myeloma (NDMM): results from the Connect MM Registry","volume":"20","author":"Jagannath","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"2024010916393201600_bib4","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3324\/haematol.2015.129189","article-title":"Treatment of relapsed and refractory multiple myeloma","volume":"101","author":"Sonneveld","year":"2016","journal-title":"Haematologica"},{"key":"2024010916393201600_bib5","volume-title":"ABECMA (idecabtagene vicleucel). Package insert","year":"2021"},{"issue":"8","key":"2024010916393201600_bib6","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2024010916393201600_bib7","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"2024010916393201600_bib8","first-page":"26","article-title":"Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in patients with relapsed and refractory multiple myeloma: updated results from phase 1 CRB-401 study","volume":"9","author":"Lin","year":"2020","journal-title":"Blood"},{"issue":"6","key":"2024010916393201600_bib9","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-021-00507-2","article-title":"KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma","volume":"11","author":"Jagannath","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"2024010916393201600_bib10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1023\/A:1022268103136","article-title":"Myeloma and race: a review of the literature","volume":"22","author":"Benjamin","year":"2003","journal-title":"Cancer Metastasis Rev"},{"issue":"7","key":"2024010916393201600_bib11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41408-018-0102-7","article-title":"Disease and outcome disparities in multiple myeloma: exploring the role of race\/ethnicity in the Cooperative Group clinical trials","volume":"8","author":"Ailawadhi","year":"2018","journal-title":"Blood Cancer J"},{"issue":"16","key":"2024010916393201600_bib12","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1002\/cncr.30747","article-title":"Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: a CIBMTR report","volume":"123","author":"Schriber","year":"2017","journal-title":"Cancer"},{"issue":"12","key":"2024010916393201600_bib13","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1002\/cam4.1246","article-title":"Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis","volume":"6","author":"Ailawadhi","year":"2017","journal-title":"Cancer Med"},{"issue":"20","key":"2024010916393201600_bib14","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1182\/bloodadvances.2019000308","article-title":"Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis","volume":"3","author":"Ailawadhi","year":"2019","journal-title":"Blood Adv"},{"issue":"7","key":"2024010916393201600_bib15","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jtct.2022.04.008","article-title":"Socioeconomic and racial disparity in chimeric antigen receptor T cell therapy access","volume":"28","author":"Ahmed","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"23","key":"2024010916393201600_bib16","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1002\/cam4.4797","article-title":"Demographic differences among patients treated with chimeric antigen receptor T-cell therapy in the United States","volume":"11","author":"Emole","year":"2022","journal-title":"Cancer Med"},{"issue":"25","key":"2024010916393201600_bib17","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","article-title":"Racial disparities in incidence and outcome in multiple myeloma: a population-based study","volume":"116","author":"Waxman","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2024010916393201600_bib18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-022-00633-5","article-title":"Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study","volume":"12","author":"Dong","year":"2022","journal-title":"Blood Cancer J"},{"issue":"23","key":"2024010916393201600_bib19","doi-asserted-by":"crossref","first-page":"6040","DOI":"10.1182\/bloodadvances.2022007676","article-title":"The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes","volume":"6","author":"Faruqi","year":"2022","journal-title":"Blood Adv"},{"issue":"16 suppl","key":"2024010916393201600_bib20","article-title":"Real-world outcomes of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) by race and ethnicity","volume":"40","author":"Locke","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"2024010916393201600_bib21","article-title":"Inferior outcomes among black patients with childhood acute lymphoblastic leukemia following tisagenlecleucel","author":"Baggott","year":"8-12  2021","journal-title":"Poster presented at: 2021 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR"},{"issue":"11","key":"2024010916393201600_bib22","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2024010916393201600_bib23","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"2024010916393201600_bib24","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/107327481602300404","article-title":"Barriers to clinical trial enrollment in racial and ethnic minority patients with cancer","volume":"23","author":"Hamel","year":"2016","journal-title":"Cancer Control"},{"key":"2024010916393201600_bib25","doi-asserted-by":"crossref","first-page":"102479","DOI":"10.1016\/j.ctrv.2022.102479","article-title":"Toxicities following CAR-T therapy for hematological malignancies","volume":"111","author":"Hernani","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"2024010916393201600_bib26","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1373\/clinchem.2007.098996","article-title":"Ethnic differences in C-reactive protein concentrations","volume":"54","author":"Kelley-Hedgepeth","year":"2008","journal-title":"Clin Chem"},{"issue":"3","key":"2024010916393201600_bib27","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1017\/S095026880700831X","article-title":"Ethnic difference in the relationship between acute inflammation and serum ferritin in US adult males","volume":"136","author":"Pan","year":"2008","journal-title":"Epidemiol Infect"},{"issue":"8","key":"2024010916393201600_bib28","doi-asserted-by":"crossref","first-page":"e2228877","DOI":"10.1001\/jamanetworkopen.2022.28877","article-title":"Geographic and racial disparities in access to chimeric antigen receptor-T cells and bispecific antibodies trials for multiple myeloma","volume":"5","author":"Alqazaqi","year":"2022","journal-title":"JAMA Netw Open"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/1\/251\/2180445\/blooda_adv-2023-010894-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/1\/251\/2180445\/blooda_adv-2023-010894-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T16:40:47Z","timestamp":1704818447000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/1\/251\/498328\/Racial-and-ethnic-differences-in-clinical-outcomes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,9]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010894","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,9]]}}}